IP Watchdog

NOVEMBER 13, 2024

The petition was filed on September 11, 2024, by Salix Pharmaceuticals and stems from an April 2024 precedential decision of the Federal Circuit affirming a district court’s final judgment that certain claims of several patents owned by Salix for a drug used to treat irritable bowel syndrome (IBS) and other ailments were invalid as obvious.

Pharmaceuticals

Complex Discovery

JULY 12, 2024

Editor’s Note: In a legal confrontation that could significantly impact the pharmaceutical industry, AbbVie has petitioned the U.S. Circuit Court of Appeals’ February decision that deemed AbbVie’s patent litigation against Perrigo a “sham.” has petitioned the U.S.

Pharmaceuticals

Insurance Journal

JANUARY 27, 2025

is facing its first jury trial over claims the company wrongfully marketed its lucrative Gardasil cancer vaccine as safe, the latest high-stakes litigation for the pharmaceutical giant. Merck & Co. Lawyers for a Los Angeles woman will argue Monday that …

Pharmaceuticals

IP Watchdog

MARCH 17, 2022

Intel and Xilinx combined to cancel a number of litigation-funded chip patents from Arbor Global Strategies and FG SRC LLC [the latter funded by Freeman Capital Partners]; a number of Fortress-funded subsidiaries were challenged; another 29 IP Edge subsidiary suits; some interesting pharmaceutical action; and companies WebRoot and OpenText, inc.

Litigation

Insurance Journal

DECEMBER 12, 2024

COLUMBUS, Ohio (AP) The Ohio Supreme Court ruled last Tuesday that the state’s product liability law prohibits counties from bringing public nuisance claims against national pharmaceutical chains as they did as part of national opioid litigation, a decision that …

Pharmaceuticals

IP Watchdog

AUGUST 24, 2022

On August 19, British brand name pharmaceutical firm GlaxoSmithKline (GSK) filed a brief with the U.S. Supreme Court opposing a petition for writ of certiorari filed by generic drugmaker Teva Pharmaceuticals. Teva’s petition appeals a decision by the U.S.

Pharmaceuticals

IP Watchdog

MAY 14, 2025

The Unified Patent Court (UPC) has quickly become an important forum for pharmaceutical and biotech patent disputes in Europe. Innovators and generic or biosimilar companies are now coordinating multi-front strategies engaging the UPC for pan-European relief while leveraging EPO opposition and selecting national litigations.

Litigation

IP Watchdog

OCTOBER 10, 2024

The letter sent last week was organized by Lawyers for Civil Justice (LCJ) and signed by some of the world’s largest and most well-known corporations, including all of the major internet platforms, pharmaceutical and automotive companies.

Litigation

IP Watchdog

AUGUST 6, 2021

Court of Appeals for the Federal Circuit (CAFC) on Thursday underscored its October 2020 ruling that generic company, Teva Pharmaceuticals, was liable for induced infringement of GlaxoSmithKline’s (GSK’s) patent directed to a method of treating Congestive Heart Failure (CHF) using carvedilol.

Pharmaceuticals

IP Watchdog

MAY 7, 2025

Sun Pharmaceutical Industries, Ltd. Today, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Incyte Corp. dismissing Incytes appeal from post-grant review (PGR) proceedings at the Patent Trial and Appeal Board (PTAB) for lack of Article III standing.

Pharmaceuticals

IP Watchdog

AUGUST 31, 2021

District Court for the Southern District of Florida ruled against plaintiff Vital Pharmaceuticals, Inc.’s In each of these opinions, the court noted the absence of survey evidence (or, in the Vital Pharmaceuticals case, the inadequacy of an “almost comically flawed” survey). On August 3, 2021, the U.S. On June 7, 2021, the U.S.

Case Law

IP Watchdog

AUGUST 16, 2021

Court of Appeals for the Federal Circuit today issued two precedential decisions and one nonprecedential decision in cases involving Teva Pharmaceuticals and Eli Lilly, delivering wins and losses for each company.

Pharmaceuticals

IP Watchdog

SEPTEMBER 2, 2021

Court of Appeals for the Federal Circuit (CAFC) on Wednesday upheld a Delaware district court’s ruling that Belcher Pharmaceuticals Inc.’s In a precedential decision written by Judge Reyna, the U.S. s Chief Science Officer engaged in inequitable conduct, making its U.S. 9,283,197 unenforceable. Belcher brought the suit against Hospira, Inc.

Pharmaceuticals

Insurance Journal

SEPTEMBER 9, 2024

Scott announced that one week before its trial is to begin, the city has reached an $80 million settlement with Teva Pharmaceuticals to resolve the city’s claims over the firm’s role in fueling Baltimore’s opioid epidemic. Mayor Brandon M. Teva …

Pharmaceuticals

IP Watchdog

JANUARY 24, 2023

Last week, Novartis Pharmaceuticals followed through on its September 2022 promise that it would appeal the U.S. Court of Appeals for the Federal Circuit’s (CAFC’s) June 2022 decision invalidating its patent for a dosing regimen for its multiple sclerosis drug Gilenya to the U.S.

Pharmaceuticals

IP Watchdog

NOVEMBER 6, 2023

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Actelion Pharmaceuticals Ltd. Mylan Pharmaceuticals Inc. Today, the U.S. vacating an infringement judgment against Mylan in the Northern District of West Virginia.

Evidence

IP Watchdog

JULY 29, 2021

Earlier today, the Senate Judiciary Committee held an Executive Business Meeting in which the Committee discussed and favorably reported four bills aimed at reducing prescription drug prices for consumers and curbing perceived abuses of the patent system by brand pharmaceutical companies.

Pharmaceuticals

IP Watchdog

SEPTEMBER 30, 2022

Court of Appeals for the Federal Circuit (CAFC) earlier today upheld a Patent Trial and Appeal Board (PTAB) decision finding that Mylan Pharmaceuticals, Inc. In its third precedential patent opinion this week, the U.S. failed to show that certain claims of Merck Sharp & Dohme Corp.’s

Pharmaceuticals

IP Watchdog

JUNE 25, 2024

Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision today reversing a district court’s grant of Hikma Pharmaceuticals’ motion to dismiss Amarin Pharma, Inc.’s s complaint against it for induced infringement.

Pharmaceuticals

IP Watchdog

NOVEMBER 8, 2021

Mylan Pharmaceuticals Inc. On November 5, the U.S. Court of Appeals for the Federal Circuit (CAFC) issued a precedential decision in Celgene Corp.

Pharmaceuticals

IP Watchdog

SEPTEMBER 22, 2022

Novartis Pharmaceuticals announced today that it will appeal the U.S. Court of Appeals for the Federal Circuit’s (CAFC’s) June decision invalidating its patent for a dosing regimen for its multiple sclerosis drug Gilenya to the U.S. Supreme Court, after the CAFC denied its request to rehear the case.

Pharmaceuticals

IP Watchdog

MARCH 30, 2023

Solicitor General on Wednesday filed an amicus brief with the United States Supreme Court advising it to grant Teva Pharmaceuticals’ petition for writ of certiorari relating to generic manufacturers’ liability for infringement through the use of “skinny labels” on generic drugs. The SG’s brief said that the U.S.

Pharmaceuticals

IP Watchdog

JULY 21, 2022

Mylan Pharmaceuticals Inc. Last week, the U.S. Supreme Court received several amicus briefs filed in support of the petition for writ of certiorari filed in Biogen International GmbH v. If cert is granted, this case will ask the nation’s highest court to clarify the written description requirement under 35 U.S.C. §

Pharmaceuticals

InHouseBlog

APRIL 8, 2022

VP, Litigation & Employment Law , www.princetonlegal.com (Princeton, NJ). Senior Director, Compliance Risk Navigation , Regeneron Pharmaceuticals (Tarrytown, NY). Regulatory Litigation Attorney , Southern California Edison (Hybrid Remote). Director, IP Litigation , Inscripta, Inc. Legal Counsel , TuneIn (Remote).

Real Estate

Insurance Journal

DECEMBER 2, 2024

The province of British Columbia can bring a class action lawsuit against pharmaceutical companies for opioid harms on behalf of multiple governments across Canada, the country’s Supreme Court ruled on Friday. In 2018, BC sued more than 40 drug manufacturers, …

Pharmaceuticals

IP Watchdog

FEBRUARY 1, 2024

Department of Health and Human Services (HHS) made its initial offers to pharmaceutical companies pursuant to the Biden Administration’s Inflation Reduction Act of 2022 (IRA), which allows the U.S. Today, the U.S. Government to “negotiate” Medicare drug prices under a set framework based upon the amount of time a drug has spent on the market.

Pharmaceuticals

IP Watchdog

APRIL 29, 2024

The COVID-19 vaccine was quickly rolled out compared to other vaccines in the past and many pharmaceutical companies benefited financially. However, GSK contends their competitors, Pfizer Inc. and Pharmacia & Upjohn Co. LLC (collectively Pfizer) and BioNTech SE, BioNTech Manufacturing GMBH and BioNTech US Inc.

Manufacturing

IP Watchdog

OCTOBER 20, 2022

The People’s Vaccine Alliance, a coalition of over 100 organizations, issued a statement this week alleging that the pharmaceutical industry is attempting to tighten its control of the world’s pandemic response plans.

Pharmaceuticals

IP Watchdog

JANUARY 20, 2022

In denying petitions from consumer tech giant Apple and generic pharmaceutical firm Mylan Laboratories, SCOTUS has ended the latest challenge to the PTAB’s NHK/Fintiv rule, which has raised the ire of many entities who have found the PTAB to be a very valuable backdoor towards patent invalidation outside of U.S. district court.

Pharmaceuticals

IP Watchdog

JULY 25, 2023

Patent 9,593,066 cover methods of treating pulmonary hypertension and pharmaceutical compositions comprising treprostinil—Tyvaso is an inhaled solution formulation of treprostinil. Patent 10,716,793 and U.S. United Therapeutics also owns a new drug application (NDA) for Tyvaso, No. 022387.

Pharmaceuticals

IP Watchdog

AUGUST 18, 2022

Court of Appeals for the Federal Circuit (CAFC) today affirmed a district court’s finding that Eagle Pharmaceuticals, Inc.’s s abbreviated new drug application (ANDA) does not infringe two patents owned by Par Pharmaceutical, Inc., In its third precedential patent decision this week, the U.S.

Pharmaceuticals

IP Watchdog

MARCH 12, 2023

The brief responds to arguments raised both by rival pharmaceutical firm Sanofi and the U.S. Supreme Court in its appeal of the invalidation of its patent claims covering antibodies effective at blocking low-density lipoprotein (LDL) cholesterol receptors.

Pharmaceuticals

Securities Docket

SEPTEMBER 17, 2024

Vinson & Elkins today announced that Jason Halper and Sara (Bussiere) Brauerman have joined the firm as New York-based partners in the firm’s Litigation Practice. Halper is a nationally recognized trial lawyer who brings significant commercial litigation experience.

Litigation

IP Watchdog

AUGUST 7, 2022

recently in Novartis Pharmaceuticals Corp. But in Novartis Pharmaceuticals v. Talk about snatching victory from the jaws of defeat! That is precisely what the Federal Circuit did for HEC Pharm Co. Accord Healthcare Inc. 2021-1070).

Pharmaceuticals

IP Watchdog

MARCH 26, 2023

Sanofi, a case with the parties and 27 Amici, including the United States, weighing in on whether and how the Court should address the enablement requirement of Section 112 in the context of genus claims, and in particular, genus claims to antibodies in the pharmaceutical sciences.

Jury Instructions

IP Watchdog

SEPTEMBER 16, 2024

Last week, Patients for Affordable Drugs (“P4AD”) became the latest amicus to file a brief with the U.S. Court of Appeals for the Third Circuit in Bristol Myers Squibb Co. Becerra et al.

Pharmaceuticals

IP Watchdog

AUGUST 4, 2022

Court of Appeals for the Eleventh Circuit affirmed a district court’s ruling against Vital Pharmaceuticals, Inc. On Wednesday, August 3, the U.S. VPX) in the form of sanctions for violating its discovery obligations in a trade dress dispute with Monster Energy Company.

Pharmaceuticals